Ipro 2 professional cgm

Manufactured by Medtronic

Sourced in United States

The IPro™2 Professional CGM is a continuous glucose monitoring device designed for healthcare professionals. It measures and records glucose levels in the interstitial fluid over an extended period, providing healthcare providers with detailed glucose data to support patient treatment and management.

Automatically generated - may contain errors

Lab products found in correlation

Carelink ipro, by Medtronic (3 mentions) Onetouch ultra 2 blood glucose meter, by LifeScan (1 mentions) Freestyle navigator 2, by Abbott (1 mentions) Guardian real time, by Medtronic (1 mentions) Freestyle optium neo blood glucose meter, by Abbott (1 mentions) Onetouch ultra2, by LifeScan (1 mentions) Carelink therapy management soft ware, by Medtronic (1 mentions)

15 protocols using ipro 2 professional cgm

Continuous Glucose Monitoring in Diabetes Management

Check if the same lab product or an alternative is used in the 5 most similar protocols

A blinded CGM [iPro^®2 Professional CGM; Medtronic Diabetes, Northridge, CA; median absolute relative difference: 11.1%] was worn for a 7-day period to measure interstitial glucose levels in real time throughout the day and night. At the baseline visit, study participants inserted the iPro^®2 CGM system with the Enlite™ sensor into abdominal subcutaneous adipose tissue. Participants were carefully instructed on the use and maintenance of the CGM and advised to calibrate the sensor before eating and before bed with an iPro2 compatible glucometer (OneTouch^® Ultra^® 2). The Enlite™ sensor measured interstitial glucose level every 5 minutes within the 3-147 mmol/mol (40-400 mg/dL) range. On the last day of the CGM wear week, participants were reminded to send the devices back using a pre-paid box/envelope. CGM data were downloaded with CareLink iPro^® System and uploaded to the coordinating center for data processing. As part of blinding, no communication from the device was available to participants.

Kahkoska A.R., Adair L.A., Aiello A.E., Burger K.S., Buse J.B., Crandell J., Maahs D.M., Nguyen C.T., Kosorok M.R, & Mayer-Davis E.J. (2019). Identification of clinically-relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. Pediatric diabetes, 20(5), 556-566.

+ Open protocol

+ Expand

Continuous Glucose Monitoring for Glycemic Response

Check if the same lab product or an alternative is used in the 5 most similar protocols

Continuous glucose monitoring (CGM) (iPro™2 Professional CGM-Medtronic MiniMed, Northbridge, CA, USA) was used to measure glycaemic response, defined as the primary outcome. The insertion was performed on Day 1 at 17:00 and the sensor was removed on Day 3 of the study at 9:00. Data was collated and processed using online software (Medtronic Diabetes CareLink iPro; carelink.minimed.eu). The data reported in this paper represent 24 h interstitial glucose readings recorded every 5 min from 6:00 on Day 2 to 6:00 on Day 3. During each test session, the CGM sensor was calibrated against finger-stick blood glucose measurements four times a day before every meal and before sleeping using the OneTouch®Ultra®2 blood glucose meter (LifeScan, Inc., Milpitas, CA, USA). A cross-over design with a minimum of 8 subjects would be sufficient to detect a 15% change in area under the glucose curve (24 h) with a power of 0.85 at a significance level of 0.05 as adapted from Brynes et al. [25 (link), 26 (link)].

Camps S.G., Kaur B., Quek R.Y, & Henry C.J. (2017). Does the ingestion of a 24 hour low glycaemic index Asian mixed meal diet improve glycaemic response and promote fat oxidation? A controlled, randomized cross-over study. Nutrition Journal, 16, 43.

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Newborns

Check if the same lab product or an alternative is used in the 5 most similar protocols

As soon as possible following delivery (aiming for within 4 hours), an appropriately trained member of the research team fitted the newborn infant with a masked CGM device (iPro™2 Professional CGM, Medtronic, Northridge, CA, USA). The sensors were inserted into the lateral aspect of the infant's thigh. While infants had the sensor in situ, their routine blood glucose monitoring samples were used to calibrate the CGM. Concurrent sampling was performed for measurement of infant blood ketones. There were no additional blood glucose samples taken from infants as a result of this study.

Stewart Z.A., Thomson L., Murphy H.R, & Beardsall K. (2019). A Feasibility Study of Paired Continuous Glucose Monitoring Intrapartum and in the Newborn in Pregnancies Complicated by Type 1 Diabetes. Diabetes technology & therapeutics, 21(1).

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Pregnant T1D

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pregnant CGM users were approached about potential participation in the study during their third trimester. Those who wished to participate provided informed consent for themselves and assent for their neonate, with parental written consent for neonates confirmed within 24 hours of delivery. Inclusion criteria included maternal familiarity with masked or real-time CGM, intensive insulin therapy using either multiple daily injections of insulin (MDI) or insulin pump therapy, and singleton pregnancy. Exclusion criteria included known congenital anomaly or neonates with severe respiratory distress.
Pregnant women with T1D had a CGM sensor inserted 2-3 days prior to anticipated delivery.
Participants already using the Guardian® REAL-Time or MiniMed Minilink® CGM (both Medtronic, Northridge, CA) continued their usual CGM. Participants using the Freestyle Navigator II (Abbott Diabetes Care) were fitted with an additional masked CGM sensor for measurements used in this study (iPro™ 2 Professional CGM, Medtronic, Northridge, CA, USA). Participants were asked to measure capillary glucose concentration using their routine glucometer and to record at least 4 daily readings.

+ Open protocol

+ Expand

Continuous Glucose Monitoring for Glycemic Response

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Continuous glucose monitoring (CGM) (iPro™2 Professional CGM-Medtronic MiniMed, Northbridge, CA, USA) was used to measure glycemic response, defined as the primary outcome. The insertion was performed on Day 1 at approximately 16:00 and the sensor was removed on Day 3 of the study at 09:00. Data was collated and processed using online software (Medtronic Diabetes CareLink iPro; carelink.minimed.eu). The data reported in this paper represent 24 h interstitial glucose readings recorded every 5 min from the start of breakfast on Day 2 at approximately 09:00 until 24 h later at approximately 09:00 on Day 3. During each test session, the CGM sensor was calibrated against finger-stick blood glucose measurements four times a day before every meal and before sleeping using the FreeStyle Optium Neo Blood Glucose meter (Abbott Laboratories). A cross-over design with a minimum of 8 subjects would be sufficient to detect a 15% change in area under the glucose curve (24 h) with a power of 0.85 at a significance level of 0.05 [36 (link)].

Camps S.G., Kaur B., Lim J., Loo Y.T., Pang E., Ng T, & Henry C.J. (2021). Improved Glycemic Control and Variability: Application of Healthy Ingredients in Asian Staples. Nutrients, 13(9), 3102.

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Glycemic Response

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Continuous glucose monitoring (CGM) (iPro™2 Professional CGM-Medtronic MiniMed, Northbridge, CA, USA) was used to measure glycaemic response, defined as the primary outcome. The insertion of the sensor was performed on day 1 at 17:00 and the sensor was removed on day 3 at 10:00. Data was collated and processed using online software (Medtronic Diabetes CareLink iPro) [32 ]. The data reported in this paper represent interstitial glucose readings recorded every 5 min for up to 42 h. During each test session, the CGM sensor was calibrated against finger-stick blood glucose measurements four times a day before every meal and before sleeping using a blood glucose meter (OneTouch^®Ultra^®2, LifeScan, Inc., Milpitas, CA, USA). A cross-over design with a minimum of eight subjects would be sufficient to detect a 15% change in area under the glucose curve (24 h) with a power of 0.85 at a significance level of 0.05 [33 (link)].

Henry C.J., Kaur B., Quek R.Y, & Camps S.G. (2017). A Low Glycaemic Index Diet Incorporating Isomaltulose Is Associated with Lower Glycaemic Response and Variability, and Promotes Fat Oxidation in Asians. Nutrients, 9(5), 473.

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Pediatrics

Check if the same lab product or an alternative is used in the 5 most similar protocols

At baseline and at 6 and 18 months post-randomization, a blinded continuous glucose monitor (CGM; iPro^®2 Professional CGM; Medtronic Diabetes, Northridge, CA) was worn for a seven-day period to measure interstitial glucose levels in real time throughout the day and night. Cutpoints for glucose used to describe hypoglycemia were established according to recommended values.^{23 (link)} Height was measured using a stadiometer, and weight was measured to the nearest 0∙1 kg using an electronic scale. Body mass index (BMI, weight (kg) / height (m)²) was calculated and then converted to an age- and sex-specific BMI z-score according to the Centers for Disease Control and Prevention growth charts. Blood pressure was measured after five minutes of rest using an aneroid manometer. The second and third of three measures were averaged for systolic and diastolic pressures.

Mayer-Davis E.J., Maahs D.M., Seid M., Crandell J., Bishop F.K., Driscoll K.A., Hunter C.M., Kichler J.C., Standiford D, & Thomas J.M. (2018). The Flexible Lifestyles Empowering Change (FLEX) Intervention for Adolescents with Type 1 Diabetes: Randomized Clinical Trial Results for Effect on Metabolic Status, Diabetes Related Behaviors, and Quality of Life. The Lancet. Child & adolescent health, 2(9), 635-646.

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols

A blinded CGM [iPro^®2 Professional CGM; Medtronic Diabetes, Northridge, CA; median absolute relative difference: 11.1%]²¹ was worn for a 7-day period to measure interstitial glucose levels in real time throughout the day and night. At the baseline and 6-month visits, study participants inserted the iPro^®2 CGM system with the Enlite™ sensor into abdominal subcutaneous adipose tissue. Participants were carefully instructed on the use and maintenance of the CGM and advised to calibrate the sensor before eating and before bed with an iPro2 compatible glucometer (OneTouch^® Ultra^® 2). The Enlite™ sensor measured interstitial glucose level every 5 minutes within the 40–400 mg/dL range. On the last day of the CGM wear week, participants were reminded to send the devices back, using the pre-paid box/envelope provided to them. CGM data were downloaded with CareLink iPro^® System and uploaded to the coordinating center for data processing. As part of blinding, no communication from the device was available to participants. Cut-points for glucose used to describe hypoglycemia were established according to recommended International Hypoglycemia Study Group values.^{22 (link),23 (link)}

Igudesman D., Crandell J., Zhong V.W., Sarteau A.C., Kahkoska A.R., Corbin K., Pratley R., Kosorok M.R., Maahs D.M, & Mayer-Davis E.J. (2020). Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. Pediatric diabetes, 21(8), 1475-1484.

+ Open protocol

+ Expand

Continuous Glucose Monitoring in Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Clinical characteristics were collected including gender, age, blood pressure, BMI, chronic complications associated with diabetes, and doses of insulin injection. Clinical laboratory measurements included HbA1c, C-peptide levels, urine microalbumin to creatinine ratio (UACR), and liver and renal function.
All the participants were monitored for 72 consecutive hours with a CGM instrument (iPro™2 Professional CGM, Medtronic). Real-time data were masked to the participants and retrospectively analyzed by the clinician. Sensors were inserted subcutaneously and calibrated according to the standard recommendations of the manufacturers. During the period of CGM, capillary glucose was tested (COUNTER TS, Ascensia Diabetes Care Inc.) seven times every day, including blood glucose before and after three meals as well as at bedtime.
Raw data from CGM records were uploaded using CareLink Therapy Management Soft-ware (Medtronic). Indices including standard deviation (SD), the largest amplitude of glucose excursions (LAGE), mean amplitude of glycemic excursions (MAGE), low blood glucose index (LBGI) as well as mean blood glucose (MBG), and mean absolute glucose (MAG) were calculated to estimate blood glucose variability.

Ling Q., Lu J., Li X., Qiao C., Zhu D, & Bi Y. (2020). Value of Capillary Glucose Profiles in Assessing Risk of Nocturnal Hypoglycemia in Type 1 Diabetes Based on Continuous Glucose Monitoring. Diabetes Therapy, 11(4), 915-925.

+ Open protocol

+ Expand

Blinded CGM for Interstitial Glucose Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols

A blinded CGM [iPro^®2 Professional CGM; Medtronic Diabetes, Northridge, CA; median absolute relative
difference: 11.1% (20 )] was worn for a 7-day period to measure interstitial glucose
levels in real time throughout the day and night. At the baseline visit, study participants inserted the
iPro^®2 CGM system with the Enlite™ sensor into abdominal subcutaneous adipose tissue.
Participants were carefully instructed on the use and maintenance of the CGM and advised to calibrate the sensor before eating
and before bed with an iPro2 compatible glucometer (OneTouch^® Ultra^® 2). The
Enlite™ sensor measured interstitial glucose level every 5 minutes within the 40–400 mg/dL range. On the
last day of the CGM wear week, participants were reminded to send the devices back, using the pre-paid box/envelope provided
to them. CGM data were downloaded with CareLink iPro^® System and uploaded to the coordinating center for
data processing. As part of blinding, no communication from the device was available to participants. Cut-points for glucose
used to describe hypoglycemia were established according to recommended IHSG values (10 (link), 21 (link)). All CGM-variables were stratified by day (6:00 AM – 11:59 PM)
and night (12:00 AM – 5:59 AM) (21 (link)).

Kahkoska A.R., Crandell J., Driscoll K.A., Kichler J.C., Seid M., Mayer-Davis E.J, & Maahs D.M. (2019). Dysglycemia among youth with type 1 diabetes and suboptimal glycemic control in The Flexible Lifestyle Empowering Change (FLEX) trial. Pediatric diabetes, 20(2), 180-188.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!